Clinical trial: five or ten cycles of granulocyte–monocyte apheresis show equivalent efficacy and safety in ulcerative colitis

Dignaß, Axel; Eriksson, Anders; Kilander, Anders; Puķītis, Aldis; Rhodes, Jonathan M.; Vavricka, Stephan R.

doi:10.1111/j.1365-2036.2010.04295.x

Cited by 31 publications

(32 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the effects of new drugs on the relapse of UC were reported recently (24)(25)(26)(27)(28)(29)(30), this effect was not observed in the current study about mesalazin. It is highly recommended to use new generations of UC drugs and increase visits of high risk patients for relapse in the region under study.…”

Section: Discussioncontrasting

confidence: 66%

Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 66%

Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran

et al. 2016

View full text Add to dashboard Cite

show abstract

“…According to this point of view, removal of activated inflammatory cells from the bloodstream seems an appealing mechanism to reduce mucosal inflammation in UC patients. In fact, several mechanisms of action of leukocytapheresis in inflammatory bowel disease have been recently proposed and reviewed [10], and some open trials and prospective series suggest the usefulness of this therapy in patients with steroid-dependent UC [11][12][13][14]. Moreover, the excellent safety profile of leukocytapheresis presents an additional argument for its use in patients that have already been exposed to the severe side effects of corticosteroids.…”

Section: Introductionmentioning

confidence: 95%

Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry

et al. 2011

View full text Add to dashboard Cite

show abstract

“…There is still a controversy regarding the optimal treatment schedule. Five sessions in 5 wk vs 10 sessions in 8 wk was shown to be similar efficient [160] . Therefore Vecchi recommended in his review the perpetuation of the traditional treatment schedule of 5 sessions in 5 wk (1/wk) as it is seems not to be inferior to the more intensive version, more convenient to the patients and more cost effective [158] .…”

Section: Granulocyte Monocyte Apheresismentioning

confidence: 82%

Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults

Leitner

Vogelsang

2016

WJGPT

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory conditions mainly of the colon and small intestine. Crohn's disease (CD) and ulcerative colitis (UC) are the most frequent types of IBD. IBD is a complex disease which arises as a result of the interaction of environmental, genetic and immunological factors. It is increasingly thought that alterations of immunological reactions of the patients to their own enterable bacteria (microfilm) may contribute to inflammation. It is characterized by mucosal and sub mucosal inflammation, perpetuated by infiltration of activated leukocytes. CD may affect the whole gastrointestinal tract while UC only attacks the large intestine. The therapeutic goal is to achieve a steroidfree long lasting remission in both entities. UC has the possibility to be cured by a total colectomy, while CD never can be cured by any operation. A lifelong intake of drugs is mostly necessary and essential. Medical treatment of IBD has to be individualized to each patient and usually starts with anti-inflammatory drugs. The choice what kind of drugs and what route administered (oral, rectal, intravenous) depends on factors including the type, the localization, and severity of the patient's disease. IBD may require immune-suppression to control symptoms such as prednisolone, thiopurines, calcineurin or sometimes folic acid inhibitors or biologics like TNF-α inhibitors or anti-integrin antibodies. For both types of disease (CD, UC) the same drugs are available but they differ in their preference in efficacy between CD and UC as 5-aminosalicylic acid for UC or budesonide for ileocecal CD. As therapeutic alternative the main mediators of the disease, namely the activated pro-inflammatory cytokine producing leukocytes can be selectively removed via two apheresis systems (Adacolumn and Cellsorba) in steroid-refractory or dependent cases. Extracorporeal photopheresis results in an increase of regulatory B cells, regulatory CD8 + T cells and T-regs Type 1. Both types of apheresis were able to induce clinical remission and mucosal healing accompanied by tapering of steroids.

show abstract

Clinical trial: five or ten cycles of granulocyte–monocyte apheresis show equivalent efficacy and safety in ulcerative colitis

Abstract: SUMMARY BackgroundUlcerative colitis is characterized by leucocyte infiltration into the colonic mucosa. Granulocyte-monocyte apheresis depletes these cells.

Cited by 31 publications

References 24 publications

Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran

Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran

Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry

Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults

Contact Info

Product

Resources

About